Search research articles
Contact Us
Filters
Showing results (91-100 of 103) with videos related to
Page
of 11
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 15, 1998
Subcutaneous interleukin-2, interferon alfa-2a, and continuous infusion of fluorouracil in metastatic renal cell carcinoma: a multicenter phase II trial. Groupe Français d'Immunothérapie
A Ravaud, B Audhuy, F Gomez, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 25, 2015
First-line treatment with sunitinib for type 1 and type 2 locally advanced or metastatic papillary renal cell carcinoma: a phase II study (SUPAP) by the French Genitourinary Group (GETUG)†
A Ravaud, S Oudard, M De Fromont, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 3, 2014
Assessing the impact of evolving evidence in renal cell carcinoma treatment: an update of the Renal Cell Carcinoma Appropriateness-based Treatment Toolkit (ReCATT)
M E Gore, J Bellmunt, T Eisen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 15, 2008
First-line bevacizumab combined with reduced dose interferon-alpha2a is active in patients with metastatic renal cell carcinoma
B Melichar, P Koralewski, A Ravaud, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 3, 2021
Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
T Powles, J Bellmunt, E Comperat, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 3, 2012
Everolimus in metastatic renal cell carcinoma: Subgroup analysis of patients with 1 or 2 previous vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapies enrolled in the phase III RECORD-1 study
E Calvo, B Escudier, R J Motzer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 15, 2024
ESMO Clinical Practice Guideline interim update on first-line therapy in advanced urothelial carcinoma
T Powles, J Bellmunt, E Comperat, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 9, 2015
RECORD-2: phase II randomized study of everolimus and bevacizumab versus interferon α-2a and bevacizumab as first-line therapy in patients with metastatic renal cell carcinoma
A Ravaud, C H Barrios, B Alekseev, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 20, 2012
Evaluation of treatment options for patients with advanced renal cell carcinoma: assessment of appropriateness, using the validated semi-quantitative RAND corporation/University of California, Los Angeles methodology
M E Gore, J Bellmunt, T Eisen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 4, 2014
Outcomes from second-line therapy in long-term responders to first-line tyrosine kinase inhibitor in clear-cell metastatic renal cell carcinoma
R Elaidi, A Harbaoui, B Beuselinck, et al.
Page
of 11
Search research articles
Search
Showing results (91-100 of 103) with videos related to
Sort By:
Page
of 11
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 15, 1998
Subcutaneous interleukin-2, interferon alfa-2a, and continuous infusion of fluorouracil in metastatic renal cell carcinoma: a multicenter phase II trial. Groupe Français d'Immunothérapie
A Ravaud, B Audhuy, F Gomez, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 25, 2015
First-line treatment with sunitinib for type 1 and type 2 locally advanced or metastatic papillary renal cell carcinoma: a phase II study (SUPAP) by the French Genitourinary Group (GETUG)†
A Ravaud, S Oudard, M De Fromont, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 3, 2014
Assessing the impact of evolving evidence in renal cell carcinoma treatment: an update of the Renal Cell Carcinoma Appropriateness-based Treatment Toolkit (ReCATT)
M E Gore, J Bellmunt, T Eisen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 15, 2008
First-line bevacizumab combined with reduced dose interferon-alpha2a is active in patients with metastatic renal cell carcinoma
B Melichar, P Koralewski, A Ravaud, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 3, 2021
Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
T Powles, J Bellmunt, E Comperat, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 3, 2012
Everolimus in metastatic renal cell carcinoma: Subgroup analysis of patients with 1 or 2 previous vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapies enrolled in the phase III RECORD-1 study
E Calvo, B Escudier, R J Motzer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 15, 2024
ESMO Clinical Practice Guideline interim update on first-line therapy in advanced urothelial carcinoma
T Powles, J Bellmunt, E Comperat, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 9, 2015
RECORD-2: phase II randomized study of everolimus and bevacizumab versus interferon α-2a and bevacizumab as first-line therapy in patients with metastatic renal cell carcinoma
A Ravaud, C H Barrios, B Alekseev, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 20, 2012
Evaluation of treatment options for patients with advanced renal cell carcinoma: assessment of appropriateness, using the validated semi-quantitative RAND corporation/University of California, Los Angeles methodology
M E Gore, J Bellmunt, T Eisen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 4, 2014
Outcomes from second-line therapy in long-term responders to first-line tyrosine kinase inhibitor in clear-cell metastatic renal cell carcinoma
R Elaidi, A Harbaoui, B Beuselinck, et al.
Page
of 11